10.72
-0.09 (-0.83%)
| Penutupan Terdahulu | 10.81 |
| Buka | 10.81 |
| Jumlah Dagangan | 334,000 |
| Purata Dagangan (3B) | 3,665,971 |
| Modal Pasaran | 10,389,445,632 |
| Harga / Pendapatan (P/E TTM) | 41.23 |
| Harga / Jualan (P/S) | 12.68 |
| Harga / Buku (P/B) | 5.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Aug 2025 |
| Margin Keuntungan | 25.99% |
| Margin Operasi (TTM) | 40.17% |
| EPS Cair (TTM) | 0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 466.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.15% |
| Nisbah Semasa (MRQ) | 6.74 |
| Aliran Tunai Operasi (OCF TTM) | 212.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 139.12 M |
| Pulangan Atas Aset (ROA TTM) | 2.88% |
| Pulangan Atas Ekuiti (ROE TTM) | 9.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | ALPHAMAB-B | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -1.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ALPHAMAB-B | 10 B | - | 41.23 | 5.23 |
| LEPU BIO-B | 10 B | - | - | 12.92 |
| ABBISKO-B | 9 B | - | 57.20 | 3.83 |
| CSTONE PHARMA-B | 9 B | - | - | 23.87 |
| FRONTAGE | 2 B | - | 104.00 | 0.790 |
| GENOR-B | 2 B | - | 54.43 | 1.47 |
|
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 49.47% |
| % Dimiliki oleh Institusi | 4.54% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |